FY2025 · ended Dec 31, 2025 · Revenue $4.34M, -35.8% YoY · Filed Jun 1, 2026
ProPhase Labs, Inc. (PRPH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.3 million and a net loss of $14.7 million. Free cash flow was -$8.3 million. As of Jun 30, 2026 it held $20,000 in cash and investments and $3.5 million in total debt.
Revenue (TTM)
$3.85M
-31.2% vs year-ago TTM
Net income (TTM)
$-22.46M
+45.8% vs year-ago TTM
Operating cash flow (TTM)
$-5.54M
+50.4% vs year-ago TTM
Free cash flow
$-8.34M
+54.8% vs prior year
EPS (TTM)
$-1.71
-121.8% vs year-ago TTM
Dividend per share
$0.30
Shares outstanding
14.02M
-66.5% vs prior year
Net cash
$-3.51M
as of Jun 30, 2026
Operating margin
-404.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 868278
- Former names
- QUIGLEY CORP (until May 18, 2010)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3M | $6.8M | $35.0M | $122.6M | $79.0M |
| Operating income | -$18.0M | -$38.6M | -$21.2M | $23.6M | $9.8M |
| Net income | -$14.7M | -$53.4M | -$16.8M | $18.5M | $6.3M |
| Diluted EPS | -$1.74 | -$26.68 | -$0.98 | $1.02 | $0.40 |
| Operating cash flow | -$8.3M | -$17.5M | -$11.9M | $28.6M | -$13.6M |
| Free cash flow | -$8.3M | -$18.4M | -$14.0M | $24.6M | -$17.9M |
| Total assets | $59.9M | $63.2M | $91.9M | $87.6M | $89.3M |
| Total liabilities | $56.4M | $55.8M | $42.5M | $24.0M | $30.7M |
| Stockholders' equity | $3.5M | $7.4M | $49.4M | $63.6M | $58.6M |
| Cash and investments | $90,000 | $3.8M | $4.7M | $17.4M | $17.2M |
| Total debt | $3.5M | $12.9M | $14.0M | $4.6M | $4.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 6, 2026 | Jul 31, 2026 |
| 10-Q/A | Amended quarterly report | Jul 9, 2026 | Mar 31, 2026 |
| 10-Q/A | Amended quarterly report | Jul 7, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Jun 30, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Jun 1, 2026 | Dec 31, 2025 |
All 923 ProPhase Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.